Very interesting opportunity here. Do you need FDA approval for your product offering? If so, when do you plan to submit for approval? Having one big initial potential partner/order is great and I hope that conversion happens. Are you actively engaging other high value target ...

Hi Kirtson! Thank you for your question, your interest in Vironix, and your investment! Welcome aboard! With regard to the FDA, our remote patient monitoring turnkey solution requires FDA approval of the physiological monitoring device itself (Bp Cuffs, Oximeters, etc ... we only use devices that are already approved). We are, indeed, engaging a variety of high-value target partners in the three primary markets that we serve: 1) Remote therapeutic and patient monitoring (B2B subscription sold...

Hi Vironix team, I am very impressed by your presentation. However, I have two very big concerns: 1) Your two very important co-founders who appeared in your promotional videos (Sriram Ramanathan and Christopher Landon) do not even put down Vironix as part of their experiences...

Thank you for your comments & questions John. I wouldn't draw any correlation between our team members' Linkedin update habits and their contribution/commitment to the team. Both Sri and Dr. Landon are dedicated and committed contributors as well as serious stakeholders in Vironix's success. With regard to your questions ... 1) Here are some links to press releases, study reports, and Dr. Swaminathan's formal advisory board position with InFoMM: https://www.prnewswire.com/news-releases/ex...

Hi Vironix Team, Thank you for the replies! I have two more questions before I invest: 1) In the slide “REVENUE PROJECTIONS”, revenue increase from 2023 to 2024 is almost 10X. However, the revenue increases for 2024-2025, 2025-2026 are 2x and 1.5x respectively. Why the drastic...

Appreciate the questions John! 1) This is a B2B strategy (not a ramp up B2C strategy) that yields larger contracts following successful completion of pilots. As such, we project a classic steep initial hockey stick breakout pattern shortly after our trials finish followed by steady, sales/marketing driven growth. 2) I agree that this is confusing ... a) $150M ARR is our estimated RPM-specific revenue potential associated with LOIs/MOUs from provider partners b) $240M ARR is our estimated RPM-...

Hi Vironix Team, Thank you again for the replies! If I read it correctly, then the numbers in the “REVENUE PROJECTIONS” slide are really conservative. I like this approach – be conservative but work hard to pleasantly surprise everyone later. You team surely have accomplished ...

We very much appreciate your kind words John! Yes, at this early stage with a massive market opportunity, a global need for our technology, and a large product pipeline, we wouldn't presume to identify a merger/acquisition vs an IPO (or vice versa) as an optimal exit. However, given our partnered go-to-market strategy, we will be well positioned for a merger/acquisition as revenue grows.

Could you link to your patent application USPTO: 63/316,078?

Thanks for your question Ray. The patent is still pending in the patent office, and hence no link is available. There is, of course, a receipt record and bibliographic information that is available.

Vironix Health Inc. Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

💸 $150M Potential ARR from Current LOIs (not guaranteed)

💸 Opportunity of all potential academic and industrial partners within our network amounts to $1.8B

🌎 TAM of ~$55B for Remote Physiological Monitoring & ~$100B for Employer Wellness Market

❤️ VIRONIX outperforms standard-of-care in detecting/triaging Heart Failure, COPD & Asthma Flare-ups

📖 R&D partnerships with Oxford University, Duke University, and Kaiser Permanente to name a few

📜 Patent Pending on early detection technology (USPTO: 63/316,078)

🏆 Voted the “2022 US Most Promising Tech Startup Founded By Indians” - Silicon India

🎖️ Recognized as one of the “7 Best Startups to Buy Now on WeFunder” - YahooFinance

Vironix Health Inc.

Remote Monitoring Software that Detects Early Heart and Lung Disease Before it’s Irreversible

$279,119

Vironix Health Inc.

Quick facts

Team profiles

Featured investor profiles

$279,119

Ask